title: Feasibility study of an alternating schedule of radiotherapy and chemotherapy in advanced uterine cervical carcinoma.
abstract: From July 1981 to April 1982, 36 patients with advanced cervical carcinoma stage III (24 patients) and stage IV (12 patients) entered a feasibility study of a radiotherapy and chemotherapy combination. The first three chemotherapy courses consisted of cis-platinum alone (50 mg/m2) and were interdigitated with radiotherapy. Six more courses composed of an association of cis-platinum (50 mg/m2) and cyclophosphamide (400 mg/m2) were given after the completion of radiotherapy. Radiotherapy was delivered in two courses of 25 Gy separated by a gap of 2 weeks. The overall 4-year survival rate was 35% (95% CI: 22%). The 4-year survival rate, cumulative loco-regional failure rate, and cumulative metastasis rate were respectively 44% (95% CI: 20%), 56% (95% CI: 21%), and 30% (95% CI: 21%) in stage III and 28% (95% CI: 27%), 83% (95% CI: 21%) and 74% (95% CI: 30%) in stage IV. The incidence of immediate and late complications was low: no patient had her radiotherapy stopped because of an intolerance and two patients had their chemotherapy stopped because of an haematological intolerance. Only one patient presented a severe late clinical complication (small bowel injury).
authors.affiliation: Department of Radiotherapy, Institut Gustave-Roussy, Villejuif, France.
authors.forename: C
authors.initials: C
authors.lastname: Haie
authors.forename: M
authors.initials: M
authors.lastname: George
authors.forename: M H
authors.initials: MH
authors.lastname: Pejovic
authors.forename: D
authors.initials: D
authors.lastname: Chassagne
authors.forename: A
authors.initials: A
authors.lastname: Gerbaulet
authors.forename: J C
authors.initials: JC
authors.lastname: Horiot
authors.forename: J
authors.initials: J
authors.lastname: Fenton
authors.forename: O
authors.initials: O
authors.lastname: Le Floch
authors.forename: J F
authors.initials: JF
authors.lastname: Heron
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D011878:Radiotherapy / Q000009:adverse effects; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents